Learning Objectives
- Summarize the findings from cardiovascular outcomes studies of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)
- Identify specific patient populations that would benefit from low-density lipoprotein
cholesterol (LDL-C) lowering utilizing PCSK9i therapies
- Apply the guidance from the latest clinical recommendations for the use of PCSK9i
- Implement strategies to overcome common obstacles and potential solutions to
increase patient access to PCSK9i